Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
PCRX affiliate submitted a Form 144 reporting proposed resale of Common Stock and related recent transactions. The filing lists Common stock tied to an options grant dated 11/04/2024 and includes sales by Shawn Cross: 7,714 shares for $193,912.22 on 04/20/2026, 2,845 shares for $71,149.18 on 04/21/2026, and 1,500 shares for $37,520.55 on 04/22/2026. The filing date shown is 04/23/2026.
Pacira BioSciences Chief Financial Officer Shawn Cross exercised stock options and sold shares in a pre-planned set of trades. Over April 20–22, he exercised options for 12,059 shares of common stock at an exercise price of $16.45 per share and sold the same number of shares in open-market transactions at weighted average prices around $25.01–$25.14 per share.
After these transactions, he directly holds 105,341 shares of Pacira common stock. The filing states that the option exercises and sales were carried out under a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-scheduled rather than opportunistic.
The issuer submitted a Form 144 notice for the proposed sale of 1,500 shares of Common Stock by Fidelity Brokerage Services LLC, dated 04/22/2026, arising from an option granted on 11/04/2024. The excerpt shows shares outstanding of 40,489,894 as of 04/22/2026. The filing also discloses recent sales by Shawn Cross of 7,714 and 2,845 shares on 04/20/2026 and 04/21/2026, respectively.
Pacira BioSciences disclosed a Form 144 reporting a proposed sale of 2,845 shares via an option-related transaction to be effected on 04/21/2026 (option granted 11/04/2024) and a reported sale of 7,714 shares by Shawn Cross on 04/20/2026 for $193,912.22.
Pacira BioSciences, Inc. submits a proxy statement seeking stockholder votes at its 2026 hybrid Annual Meeting and recommends voting FOR the company’s three director nominees and each management proposal. The company highlights its 5x30 strategy, commercial momentum for EXPAREL, ZILRETTA and iovera®, pipeline advancement (including PCRX-201 and PCRX-2002), record 2025 gross margins, $238M of cash and investments, and $150M of share repurchases completed in 2025. The board addresses recent refreshment and defends its nominees against a slate put forward by DOMA Perpetual; stockholders are urged to use the company’s BLUE proxy card.
Dimensional Fund Advisors reported beneficial ownership of 2,060,597 shares of Pacira BioSciences common stock, representing 5.1% of the class as of 03/31/2026. The filing states these shares are owned by investment company and other funds advised or sub‑advised by Dimensional, which disclaims beneficial ownership.
Pacira BioSciences (PCRX): The Vanguard Group files Amendment No. 12 to Schedule 13G/A reporting zero beneficial ownership in Common Stock. The filing states 0 shares and 0% ownership and explains an internal realignment effective January 12, 2026 that produced disaggregated reporting by Vanguard subsidiaries. The filing is signed by Ashley Grim on 03/27/2026 and lists Vanguard's Malvern address.
Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. The grant was at no cash cost per share and increases his direct holdings to 31,065 common shares equivalents.
The units vest on June 11, 2026, only if he remains in continuous service with Pacira through that date. Each restricted stock unit converts into one share of Pacira common stock upon vesting, reflecting standard, service-based director compensation rather than an open-market purchase or sale.
Pacira BioSciences Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock in an open-market transaction at a price of $22.82 per share on March 17, 2026. After this sale, he directly holds 223,640.175 shares of Pacira common stock.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Slonin previously adopted, indicating the sale was scheduled in advance rather than timed discretionarily.